Company Website
 

Contact Information:

Melanie Gabel
Cell:  480-212-6041
mgabel@atricure.com
 

Virtual Exhibit Hall Home

AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 33 million people worldwide. Electrophysiologists and cardiothoracic surgeons around the globe use AtriCure technologies for the treatment of Afib and reduction of Afib related complications. AtriCure’s Isolator® Synergy™ Ablation System is the first and only medical device to receive FDA approval for the treatment of persistent Afib. AtriCure’s AtriClip® Left Atrial Appendage (LAA) Exclusion System products are the most widely used LAA management devices in the world. For more information, visit AtriCure.com or follow us on Twitter @AtriCure.